Circulating microRNAs as potential biomarkers for psychiatric and neurodegenerative disorders

Berg, Merel M.J. van den; Krauskopf, Julian; Ramaekers, J.G.; Kleinjans, J. C. S.; Prickaerts, Jos; Briedé, Jacob J.

doi:10.1016/j.pneurobio.2019.101732

Cited by 168 publications

(111 citation statements)

References 214 publications

Supporting

Mentioning

109

Contrasting

Order By: Relevance

“…However, these results need to be confirmed in more studies. Bioinformatic analysis indicated that the serum levels of miR-519d-3p could be the bridge regulator between MCI and AD; however, this requires further verification (Tao et al, 2020). Plasma miR-92a-3P, miR-181c-5p, and miR-210-3p levels are significantly upregulated in MCI and AD patients.…”

Section: Mirnas Help With the Diagnosis Of Admentioning

confidence: 97%

MicroRNAs in Alzheimer’s Disease: Function and Potential Applications as Diagnostic Biomarkers

Wei

Wang

et al. 2020

Front. Mol. Neurosci.

View full text Add to dashboard Cite

Alzheimer's disease (AD) is the most common form of dementia. Although the incidence of AD is high, the rates of diagnosis and treatment are relatively low. Moreover, effective means for the diagnosis and treatment of AD are still lacking. MicroRNAs (miRNAs, miRs) are non-coding RNAs that play regulatory roles by targeting mRNAs. The expression of miRNAs is conserved, temporal, and tissue-specific. Impairment of microRNA function is closely related to AD pathogenesis, including the betaamyloid and tau hallmarks of AD, and there is evidence that the expression of some microRNAs differs significantly between healthy people and AD patients. These properties of miRNAs endow them with potential diagnostic and therapeutic value in the treatment of this debilitating disease. This review provides comprehensive information about the regulatory function of miRNAs in AD, as well as potential applications as diagnostic biomarkers.

show abstract

Section: Mirnas Help With the Diagnosis Of Admentioning

confidence: 97%

MicroRNAs in Alzheimer’s Disease: Function and Potential Applications as Diagnostic Biomarkers

Wei

Wang

et al. 2020

Front. Mol. Neurosci.

View full text Add to dashboard Cite

show abstract

“…microRNA (miRNA) -Definitions and Actions microRNAs (miRNA) represent a class of ∼19-23 nucleotide (nt) single-stranded non-coding RNA (sncRNA) that are important epigenetic, posttranscriptional regulators of messenger RNA (mRNA) complexity. Their diminutive size, amphipathic nature, high solubility make them extremely mobile, omnipresent throughout the brain and CNS and the smallest informationcarrying nucleic acid signaling molecules in eukaryotes yet described (Hill et al, 2014a,b;Pogue et al, 2014;Lemcke and David, 2018;Zhao et al, 2018;Lukiw, 2020a,b;van den Berg et al, 2020). To date about ∼2650 individual human miRNAs have been cataloged and characterized, however, the abundance of miRNAs in the human brain and retina number only about ∼20-35 individual, high abundance, neurologically functional species which exhibit both tissue and cell type-specific expression patterns (Burmistrova et al, 2007;Lukiw, 2007;Hill and Lukiw, 2016;Konovalova et al, 2019;Singh and Yadav, 2020;Wu and Kuo, 2020; miRBase release 22.1; October 2018 6 ; last accessed 26 August 2020).…”

Section: Traditional Pathophysiological Biomarkers For Ad Are Non-spementioning

confidence: 99%

“…Using the keywords "Alzheimer's disease' and 'miRNA") indicates that there are just under ∼13,000 publications on this topic since the original publication on selective miRNA alterations in AD brain about ∼14 years ago (Lukiw, 2007). Inspection of several of these recent reports continues to support the contention of extensive miRNA heterogeneity in both AD tissues and biofluids (ECF, CSF, and blood serum) and continues to provide no general consensus of any single miRNA that defines causation for the onset or duration of the AD pathophysiology (Moradifard et al, 2018;Peña-Bautista et al, 2019;Silvestro et al, 2019;Swarbrick et al, 2019;Condrat et al, 2020;Giorgi Silveira et al, 2020;van den Berg et al, 2020). It is becoming clear, however, that a panel of multiple AD-relevant "pro-inflammatory" or "pro-pathology" miRNAs may be useful in contributing to the diagnosis of AD at any stage of the disease.…”

Section: Informative Mirnas In Admentioning

confidence: 99%

“…These include a significant dedication of medical personnel to individual AD patients in cooperation with family and caregivers, multiple combinatorial approaches including extensive clinical assessment, intermittent brain neuroimaging over the onset and course of AD and a host of multiple molecular, genetic, epigenetic, neurophysiological, and neurobiological strategies with focus on CSF, serum biomarkers, miRNA and perhaps other sncRNA abundance in these biofluid compartments. While significant progress is being made: it is important to point out that: (i) combinatorial diagnostic methodologies incorporating molecular genetic markers such as miRNA screening combined with DNA-based gene mutation analysis, advanced MRI-or PET-neuroimaging techniques and conscientious clinical evaluations, still have difficulty in the diagnosis of AD, often requiring the stratification of AD into complex subgroups and post-mortem verification (Guerreiro et al, 2012;Pogue and Lukiw, 2018;Penner et al, 2019;Peña-Bautista et al, 2019;Guest et al, 2020;Habes et al, 2020;Hampel et al, 2020a,b;Hudon et al, 2020;Khoury and Grossberg, 2020;Sherva et al, 2014;Rossini et al, 2020;Serpente et al, 2020;Sims et al, 2020;Singh and Yadav, 2020;Swarbrick et al, 2019;Turner et al, 2020;van den Berg et al, 2020;Weller, 2020); and (ii) currently available pharmacology and strategic treatments (including targeted drug delivery) based on these diagnostic tools, in the majority of cases, still do not directly address the primary underlying cause of either EOAD or LOAD but are sadly limited to the temporary alleviation of clinical symptoms (Di Resta and Ferrari, 2019;Veitch et al, 2019;Guest et al, 2020;Khoury and Grossberg, 2020;Lewczuk et al, 2020;Patnode et al, 2020;Rahman et al, 2020).…”

Section: Microrna "Human Biochemical Individuality" and Therapeutic mentioning

confidence: 99%

See 1 more Smart Citation

microRNA-Based Biomarkers in Alzheimer’s Disease (AD)

et al. 2020

View full text Add to dashboard Cite

Alzheimer's disease (AD) is a multifactorial, age-related neurological disease characterized by complex pathophysiological dynamics taking place at multiple biological levels, including molecular, genetic, epigenetic, cellular and large-scale brain networks. These alterations account for multiple pathophysiological mechanisms such as brain protein accumulation, neuroinflammatory/neuro-immune processes, synaptic dysfunction, and neurodegeneration that eventually lead to cognitive and behavioral decline. Alterations in microRNA (miRNA) signaling have been implicated in the epigenetics and molecular genetics of all neurobiological processes associated with AD pathophysiology. These changes encompass altered miRNA abundance, speciation and complexity in anatomical regions of the CNS targeted by the disease, including modified miRNA expression patterns in brain tissues, the systemic circulation, the extracellular fluid (ECF) and the cerebrospinal fluid (CSF). miRNAs have been investigated as candidate biomarkers for AD diagnosis, disease prediction, prognosis and therapeutic purposes because of their involvement in multiple brain signaling pathways in both health and disease. In this review we will: (i) highlight the significantly heterogeneous nature of miRNA expression and complexity in AD tissues and biofluids; (ii) address how information may be extracted from these data to be used as a diagnostic, prognostic and/or screening tools across the entire continuum of AD, from the preclinical stage, through the prodromal, i.e., mild cognitive impairment (MCI) phase all the way to clinically overt dementia; and (iii) consider how specific miRNA expression patterns could be categorized using miRNA reporters that span AD pathophysiological initiation and disease progression.

show abstract

“…Among neurodegenerative disorders-related miRNAs, miR-195-5p and miR-153-3p caught our attention [51,52]. Indeed, the expression of miR-195-5p is related to physical activity [53] and Aβ accumulation, and it directly targets BACE1 and APP [54], while miR-153-3p, targeting Nrf2, is involved in the control of oxidative stress response [51,53].…”

Section: Expression Levels Of Circulating Mirnasmentioning

confidence: 99%

Apolipoprotein E polymorphism and oxidative stress in human peripheral blood cells: can physical activity reactivate the proteasome system through epigenetic mechanisms?

Piccarducci

Daniele

Polini

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Alzheimer’s Disease (AD) is characterised by proteasome activity impairment and oxidative stress, resulting in β-amyloid (Aβ) production/degradation imbalance. Apolipoprotein E (ApoE) is implicated in Aβ clearance, and ApoE ε4 isoform predisposes to AD development. Regular physical activity is known to reduce AD progression. However, the impact of ApoE polymorphism and physical exercise on Aβ production and proteasome system activity has never been investigated in human peripheral blood cells.Methods Healthy subjects were enrolled and classified based on the ApoE polymorphism (by the restriction fragment length polymorphism technique) and physical activity level (Borg Scale), dividing them in ApoE ε4/non-ε4 carriers and active/non-active subjects. The plasma antioxidant capability (AOC), the erythrocyte Aβ production/accumulation, and the nuclear factor erythroid 2-related factor 2 (Nrf2)-mediated proteasome functionality were evaluated in all groups by chromatographic and immunoenzymatic assay, respectively. Moreover, epigenetic mechanisms were investigated considering the expression of the histone deacetylase 6, employing a competitive ELISA, and the modulation of two keys miRNAs (miR-153-3p and miR-195-5p), through miRNeasy Serum/Plasma Mini Kit.Results ApoE ε4 subjects showed a reduction in plasma AOC and an increase of the Nrf2 blocker, miR-153-3p, contributing to an enhancement of the erythrocyte concentration of Aβ. Physical exercise increased plasma AOC and reduced the amount of Aβ and its precursor, involving a reduced miR-153-3p expression and a miR-195-5p enhancement.Conclusions Our data highlight the impact of ApoE genotype on the amyloidogenic pathway and the proteasome system, and suggest the positive impact of physical exercise, also through epigenetic mechanisms.

show abstract

Circulating microRNAs as potential biomarkers for psychiatric and neurodegenerative disorders

Cited by 168 publications

References 214 publications

MicroRNAs in Alzheimer’s Disease: Function and Potential Applications as Diagnostic Biomarkers

MicroRNAs in Alzheimer’s Disease: Function and Potential Applications as Diagnostic Biomarkers

microRNA-Based Biomarkers in Alzheimer’s Disease (AD)

Apolipoprotein E polymorphism and oxidative stress in human peripheral blood cells: can physical activity reactivate the proteasome system through epigenetic mechanisms?

Contact Info

Product

Resources

About